ANINEWSNIH Grantees Sharpen Understanding of Antibodies That May Cut Risk of HIV …Infection Control TodayWhat immune response should a vaccine elicit to prevent HIV infection? Two studies published online today bring scientists closer to answering th…
Daily News & Analysis |
NIH grantees sharpen understanding of antibodies that may cut risk of HIV …
EurekAlert (press release) What immune response should a vaccine elicit to prevent HIV infection? Two studies published online today bring scientists closer to answering this question by identifying previously unrecognized attributes of antibodies that appear to have reduced the … Past HIV vaccine trials pave way for new treatmentDaily News & Analysis Lupus may end up saving livesVOXXI |
The Utah People’s Post |
Biogen Faces Delay in FDA Action Date – Analyst Blog
NASDAQ In addition to Plegridy, Biogen has daclizumab in its MS pipeline. Biogen and partner AbbVie ( ABBV ) are conducting a two-year phase III study (DECIDE) on daclizumab with results due later this year. Biogen is also looking to expand Tysabri’s label … Biogen Idec Inc (NASDAQ:BIIB): A Biotech Pioneer With A Stellar FutureWallStreetPR |
|
CLL patients more prone to infections due to reduced number of antibodies
News-Medical.net People with chronic lymphocytic leukaemia (CLL) are essentially more prone to infections such as varicella, influenza or pneumococci due to the reduction in the number of antibodies that their condition causes. Researchers at the MedUni Vienna’s … |
Science World Report |
Biogen Faces Delay in FDA Action Date
Zacks.com Biogen is also looking to expand Tysabri’s label and is conducting a phase IIIb study (ASCEND) in combination with daclizumab in patients with secondary-progressive MS – results are expected in 2015. The delay in Plegridy’s approval date should not be … Biogen Idec Inc (NASDAQ:BIIB): A Biotech Pioneer With A Stellar FutureWallStreetPR |
Biogen Idec Inc (NASDAQ:BIIB): A Biotech Pioneer With A Stellar FutureWallStreetPRDaclizumab for RRMS is another drug in the pipeline. Tysabri is being developed for the treatment of SPMS. If this pans out, Tysabri sales might reach a peak of $5.2 bill…
|
People with leukaemia are more prone to infection – but not from one …
HealthCanal.com (Vienna ) People with chronic lymphocytic leukaemia (CLL) are essentially more prone to infections such as varicella, influenza or pneumococci due to the reduction in the number of antibodies that their condition causes. Researchers at the MedUni … |
|
Woman With Lupus Develops Powerful HIV Antibodies
AIDSmeds.com HIV/AIDS Treatment News Scientists have discovered a woman with both lupus and HIV who has developed broadly neutralizing antibodies (BNAs) that have controlled her virus—findings that may help with HIV vaccine development, LiveScience reports. Publishing their findings in … |
|
Biosimilar monoclonal antibodies emerge from the pipeline on both sides of the …
Lexology (registration) The European Medicines Agency (“EMEA”) made its biosimilar monoclonal antibody guidelines effective in December 20121. Less than a year later, in September 2013, it approved Europe’s first biosimilar antibody. The drug is Inflectra which is a … |
|
New Market Study Published: Investigation Report on China Rituximab Market …
ClickPress (press release) [ClickPress, Mon Mar 17 2014] Rituximab (trade names “MabThera” by Roche, “Rituxan” by Genetech) is a chimeric monoclonal antibody against the protein CD20 approved in 1997 to treat tumor. It is very effective and shows good tolerance in the treatment … |